It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Although tissue engineering using human-induced pluripotent stem cells is a promising approach for treatment of cardiovascular diseases, some limiting factors include the survival, electrical integration, maturity, scalability, and immune response of three-dimensional (3D) engineered tissues. Here we discuss these important roadblocks facing the tissue engineering field and suggest potential approaches to overcome these challenges.
In this Comment, Ngan Huang et al. discuss recent advances in cardiovascular tissue engineering and some of the main challenges that remain in translating these advances to the clinic. The authors propose future direction for the field to focus research efforts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Cardiothoracic Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Veteran Affairs Palo Alto Health Care System, Palo Alto, USA (GRID:grid.280747.e) (ISNI:0000 0004 0419 2556)
2 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, USA (GRID:grid.470935.c); Emory University School of Medicine, Department of Pediatrics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
3 Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, USA (GRID:grid.470935.c); Division of Cardiology, Emory University, Department of Medicine, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
4 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
6 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Division of Cardiovascular Medicine, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
7 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University, Department of Mechanical Engineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); University of California at Santa Barbara, Departments of Mechanical Engineering; BioMolecular Science and Engineering; and Molecular, Cellular and Developmental Biology, Santa Barbara, USA (GRID:grid.133342.4) (ISNI:0000 0004 1936 9676)
8 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Division of Cardiovascular Medicine, Department of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University, Institute for Stem Cell Biology and Regenerative Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
9 University of Alabama at Birmingham, Department of Bioengineering, School of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)